Xencor INC 10-Q quarterly reports

Xencor, Inc. reports a significant settlement with Alexion regarding Ultomiris royalties, alongside continued investment in its clinical-stage biopharmaceutical pipeline.

Xencor reports a significant decrease in Q1 2026 revenue driven by a royalty dispute with Alexion, alongside increased R&D spending.

Biopharmaceutical company Xencor reports significantly increased revenue and a narrowed net loss for Q3 and the first nine months of 2025, driven by milestone payments and royalties, despite ongoing R&D investments.

Xencor, Inc. reported significantly increased revenue for the second quarter and first half of 2025, driven by milestone payments and royalties, while advancing multiple clinical-stage antibody therapeutics.

Xencor, Inc. announces its financial results for the first quarter of 2025, highlighting revenue growth and progress in its clinical-stage biopharmaceutical programs.

Xencor, Inc. restated its previously issued financial statements for fiscal year 2023 and the first three quarters of 2024 due to errors in accounting for a royalty transaction, research and development expenses, and state tax obligations, leading to a re-evaluation of internal controls.

Xencor restated its previously issued financial statements for the year ended December 31, 2023, and the three and six months ended June 30, 2024, due to errors in accounting for a royalty transaction, research and development expenses, and state tax obligations.

Xencor's Q1 2024 financials are restated due to errors in royalty accounting, R&D expense capitalization, and state tax obligations, leading to the identification of material weaknesses in internal controls.

Xencor's third quarter 2024 results show a net loss of $45.1 million, with a focus on advancing clinical programs and strategic collaborations.

Xencor's second quarter 2024 results show a net loss, driven by decreased collaboration revenue and an impairment charge, while the company continues to advance its clinical pipeline.

Xencor's first quarter 2024 results were impacted by a significant impairment charge related to its investment in Zenas BioPharma.